- Home
- ZG vs PODD Comparison
ZG vs PODD Comparison
Compare ZG & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZG
- PODD
- Stock Information
- Founded
- ZG 2004
- PODD 2000
- Country
- ZG United States
- PODD United States
- Employees
- ZG N/A
- PODD N/A
- Industry
- ZG Business Services
- PODD Medical/Dental Instruments
- Sector
- ZG Consumer Discretionary
- PODD Health Care
- Exchange
- ZG Nasdaq
- PODD Nasdaq
- Market Cap
- ZG 20.9B
- PODD 22.1B
- IPO Year
- ZG 2011
- PODD 2007
- Fundamental
- Price
- ZG $67.63
- PODD $333.21
- Analyst Decision
- ZG Buy
- PODD Strong Buy
- Analyst Count
- ZG 31
- PODD 18
- Target Price
- ZG $86.67
- PODD $354.17
- AVG Volume (30 Days)
- ZG 688.7K
- PODD 558.2K
- Earning Date
- ZG 10-30-2025
- PODD 11-06-2025
- Dividend Yield
- ZG N/A
- PODD N/A
- EPS Growth
- ZG N/A
- PODD N/A
- EPS
- ZG N/A
- PODD 3.45
- Revenue
- ZG $2,483,000,000.00
- PODD $2,521,800,000.00
- Revenue This Year
- ZG $17.58
- PODD $29.32
- Revenue Next Year
- ZG $14.15
- PODD $18.37
- P/E Ratio
- ZG N/A
- PODD $96.41
- Revenue Growth
- ZG 15.17
- PODD 27.11
- 52 Week Low
- ZG $56.63
- PODD $230.05
- 52 Week High
- ZG $90.22
- PODD $353.50
- Technical
- Relative Strength Index (RSI)
- ZG 36.77
- PODD 59.08
- Support Level
- ZG $68.35
- PODD $311.51
- Resistance Level
- ZG $72.10
- PODD $341.03
- Average True Range (ATR)
- ZG 2.30
- PODD 11.79
- MACD
- ZG -0.11
- PODD 1.86
- Stochastic Oscillator
- ZG 7.04
- PODD 84.08
About ZG Zillow Group Inc.
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Premier Agent and others.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.